免疫介导性血细胞减少症中抗胸腺细胞球蛋白的单中心经验及文献综述
Anti-thymocyte globulin in immune-mediated cytopenias: A monocentric experience and literature review.
作者信息
Guarnera Luca, Ahmed Arooj, Bravo-Perez Carlos, Ogbue Olisaemeka D, D'Addona Matteo, Brady Zachary, Unlu Serhan, Haddad Christopher, Mandala Aashray, Durmaz Arda, Gurnari Carmelo, Visconte Valeria, Maciejewski Jaroslaw P
机构信息
Department of Translational Hematology & Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Department of Biomedicine and Prevention, Tor Vergata University of Rome, Rome, Italy.
出版信息
Br J Haematol. 2025 Jun 12;207(1):284-8. doi: 10.1111/bjh.20165.
Anti-thymocyte globulin in multi-refractory immune-mediated cytopenia is an effective treatment, with response rate as high as 65%. Younger patients, presenting with thrombocytopenia or neutropenia, and those with LGL and STAT3 mutations appear to be more likely responsive.
抗胸腺细胞球蛋白治疗难治性免疫介导血细胞减少症疗效显著，缓解率高达65%。年轻患者、出现血小板减少或中性粒细胞减少的患者以及存在大颗粒淋巴细胞（LGL）和信号转导与转录激活因子3（STAT3）突变的患者似乎更易产生反应。
Zotero 插件